Atara Biotherapeutics Inc (ATRA) Director Carol Giltner Gallagher Sells 1,183 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 1,183 shares of Atara Biotherapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $46.50, for a total value of $55,009.50. Following the completion of the sale, the director now owns 111,286 shares of the company’s stock, valued at $5,174,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) opened at $43.65 on Thursday. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $49.90.

A number of analysts recently commented on the company. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Citigroup lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Thursday, February 15th. BidaskClub upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 13th. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cowen assumed coverage on Atara Biotherapeutics in a research report on Friday, January 26th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $30.60.

A number of hedge funds have recently made changes to their positions in ATRA. Schwab Charles Investment Management Inc. increased its position in Atara Biotherapeutics by 16.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock worth $1,302,000 after purchasing an additional 13,394 shares during the period. Alliancebernstein L.P. grew its position in shares of Atara Biotherapeutics by 49.6% during the 2nd quarter. Alliancebernstein L.P. now owns 27,740 shares of the biotechnology company’s stock worth $388,000 after buying an additional 9,200 shares during the period. Teachers Advisors LLC grew its position in shares of Atara Biotherapeutics by 2.4% during the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after buying an additional 1,110 shares during the period. TIAA CREF Investment Management LLC grew its position in shares of Atara Biotherapeutics by 7.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 67,892 shares of the biotechnology company’s stock worth $950,000 after buying an additional 4,661 shares during the period. Finally, Northern Trust Corp grew its position in shares of Atara Biotherapeutics by 12.0% during the 2nd quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock worth $4,183,000 after buying an additional 32,065 shares during the period. Hedge funds and other institutional investors own 74.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) Director Carol Giltner Gallagher Sells 1,183 Shares” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/22/atara-biotherapeutics-inc-atra-director-carol-giltner-gallagher-sells-1183-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply